321 related articles for article (PubMed ID: 29615436)
1. TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis.
Rosenblum H; Castano A; Alvarez J; Goldsmith J; Helmke S; Maurer MS
Circ Heart Fail; 2018 Apr; 11(4):e004769. PubMed ID: 29615436
[TBL] [Abstract][Full Text] [Related]
2. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.
Hanson JLS; Arvanitis M; Koch CM; Berk JL; Ruberg FL; Prokaeva T; Connors LH
Circ Heart Fail; 2018 Feb; 11(2):e004000. PubMed ID: 29449366
[TBL] [Abstract][Full Text] [Related]
3. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience.
Siddiqi OK; Mints YY; Berk JL; Connors L; Doros G; Gopal DM; Kataria S; Lohrmann G; Pipilas AR; Ruberg FL
Amyloid; 2022 Jun; 29(2):71-78. PubMed ID: 35083944
[TBL] [Abstract][Full Text] [Related]
4. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
5. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.
Judge DP; Heitner SB; Falk RH; Maurer MS; Shah SJ; Witteles RM; Grogan M; Selby VN; Jacoby D; Hanna M; Nativi-Nicolau J; Patel J; Rao S; Sinha U; Turtle CW; Fox JC
J Am Coll Cardiol; 2019 Jul; 74(3):285-295. PubMed ID: 30885685
[TBL] [Abstract][Full Text] [Related]
6. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.
Cappelli F; Baldasseroni S; Bergesio F; Perlini S; Salinaro F; Padeletti L; Attanà P; Paoletti Perini A; Moggi Pignone A; Grifoni E; Fabbri A; Marchionni N; Gensini GF; Perfetto F
Clin Cardiol; 2015 Feb; 38(2):69-75. PubMed ID: 25645201
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy.
Devesa A; Camblor Blasco A; Pello Lázaro AM; Askari E; Lapeña G; Gómez Talavera S; Taibo Urquía M; Rodríguez Olleros C; Tuñón J; Ibáñez B; Aceña Á
ESC Heart Fail; 2021 Aug; 8(4):2856-2865. PubMed ID: 33963812
[TBL] [Abstract][Full Text] [Related]
8. Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis.
Lohrmann G; Pipilas A; Mussinelli R; Gopal DM; Berk JL; Connors LH; Vellanki N; Hellawell J; Siddiqi OK; Fox J; Maurer MS; Ruberg FL
J Card Fail; 2020 Sep; 26(9):753-759. PubMed ID: 31805416
[TBL] [Abstract][Full Text] [Related]
9. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
[TBL] [Abstract][Full Text] [Related]
11. Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
Hirakawa K; Takashio S; Marume K; Yamamoto M; Hanatani S; Yamamoto E; Sakamoto K; Izumiya Y; Kaikita K; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Yamashita Y; Ando Y; Tsujita K
ESC Heart Fail; 2019 Feb; 6(1):122-130. PubMed ID: 30284755
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of Transthyretin Amyloidosis: How to Rank Drug Candidates Using X-ray Crystallography Data.
Leite JP; Costa-Rodrigues D; Gales L
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398647
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
15. Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.
Gopal DM; Ruberg FL; Siddiqi OK
Curr Heart Fail Rep; 2019 Oct; 16(5):180-188. PubMed ID: 31520266
[TBL] [Abstract][Full Text] [Related]
16. Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis.
Thenappan T; Fedson S; Rich J; Murks C; Husain A; Pogoriler J; Anderson AS
Amyloid; 2014 Jun; 21(2):120-3. PubMed ID: 24818650
[TBL] [Abstract][Full Text] [Related]
17. Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Their Common Age-Related Comorbidities.
Cioffi CL; Raja A; Muthuraman P; Jayaraman A; Jayakumar S; Varadi A; Racz B; Petrukhin K
J Med Chem; 2021 Jul; 64(13):9010-9041. PubMed ID: 34138572
[TBL] [Abstract][Full Text] [Related]
18. Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study.
Qarni TN; Jones FJS; Drachman B; Khella S; Pieretti J; Bustamante NS; Karam C
Orphanet J Rare Dis; 2024 May; 19(1):191. PubMed ID: 38720335
[TBL] [Abstract][Full Text] [Related]
19. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
20. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
Waddington-Cruz M; Ackermann EJ; Polydefkis M; Heitner SB; Dyck PJ; Barroso FA; Wang AK; Berk JL; Dyck PJB; Monia BP; Hughes SG; Tai L; Jesse Kwoh T; Jung SW; Coelho T; Benson MD; Gertz MA
Amyloid; 2018 Sep; 25(3):180-188. PubMed ID: 30169969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
